相关实验视频
Updated: Jul 19, 2025

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
USP35通过保护PKM2免受无化介导的降解,促进肝细胞癌的进展
Tao Lv1, Bo Zhang2, Chenghao Jiang1
1Laboratory of Liver Transplantation, Frontiers Science Center for Disease‑Related Molecular Network, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.
高基因特异蛋白酶35 (USP35) 的高表达与肝细胞癌 (HCC) 的预后不佳相关. 抑制USP35通过影响pyruvate kinase M2 (PKM2) 和Warburg效应来阻碍HCC细胞恶性瘤,这表明USP35是潜在的治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 肝细胞癌 (HCC) 是一种流行的主要肝癌,死亡率高.
- 在HCC进展中,全素特异蛋白酶35 (USP35) 的作用在很大程度上是未知的.
- USP35涉及到细胞增殖和线粒分裂.
研究的目的:
- 为了研究USP35在HCC中的表达.
- 分析USP35和HCC患者预后之间的关联.
- 阐明USP35在HCC恶性瘤中的功能性作用和机制.
主要方法:
- 在HCC患者队列和公共数据库中分析USP35表达.
- 在体外细胞功能实验 (增殖,迁移,入侵试验).
- 西方涂抹和无处不在测试研究USP35,PKM2无处不在和华堡效应.
主要成果:
- USP35在HCC组织中显著上调.
- 高USP35表达与患者预后不佳相关.
- 抑制USP35可以减少HCC细胞的增殖,迁移和入侵.
- USP35通过使PKM2脱,增强华堡效应来促进HCC恶性病变.
结论:
- USP35在HCC中具有致癌性,并作为预后生物标志物.
- USP35通过PKM2-Warburg效应轴调节HCC的进展.
- USP35代表了肝细胞癌治疗的潜在治疗标.
更多相关视频
10:26Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations
Published on: November 7, 2019
08:29SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
Published on: November 1, 2019
相关概念视频
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway